Terremark's industry-leadingmanaged Neil Young services for federal

Terremark's industry-leadingmanaged describes about neil young services for acoustic young reasons federal government and enterprise customers, include itsEnterprise Cloud(tm) services, managed hosting, and secure information services.The availability of Terremark's full set of products and services at NCRprovides a higher level of redundancy for the many customers interested indynamic solutions to their disaster recovery/COOP needs. In addition, Terremarkis addressing customer demand for an enterprise-class cloud computing offeringwith infrastructure based in multiple sites by adding NCR to its overallEnterprise Cloud footprint."Our ability to offer our current and potential customers a full suite ofservices from another of our world-class datacenters will only increase ouralready robust pipeline and provide our customers additional flexibility tocustomize solutions to meet their business needs," said Marvin Wheeler,Terremark's Chief Operations Officer and U.S Commercial Business UnitPresident. "Offering our Enterprise Cloud services from multiple facilitiesenhances the flexibility of the offering for our customers and takes the idea ofa 'true cloud' for IT infrastructure to the next level."Opened in June 2008, the NAP of the Capital Region is strategically located inCulpeper, Va., 60 miles from Washington, D.C. and was specifically designed toexceed standards as a Federal data communications and hosting facility offeringthe ultimate in physical security. The 30-acre campus is the ideal location forgovernment organizations, enterprises and Web 2.0 companies requiring managedinfrastructure solutions engineered to meet the needs of today's power, spaceand bandwidth-intensive mission-critical applications or hot/warm sites fordisaster recovery/COOP environments."The addition of our full suite of managed solutions enhances the valueproposition for the many existing federal government and enterprise customers atNCR, and is consistent with our strategy of offering world-class colocationservices, a premium suite of managed services and interconnection services,"said Manuel D Medina, Chairman and CEO of Terremark. "Since the facilityopened, the strong demand for Terremark's world-class IT infrastructuresolutions from such a highly secure and technologically sophisticated datacentercampus has exceeded our initial expectations and the facility continues toattract strong demand from both Federal and enterprise customers from areasthroughout the Mid-Atlantic and Northeast regions of the United States."The NCR campus can accommodate up to five, 50,000-square-foot independentdatacenter structures and a 72,000-square-foot secure office building. Eachstructure will be a secure bunker, designed to provide managed colocation spacethat meets the standards for sensitive compartmented information facilities(SCIFs) to customers who require it.About Terremark Worldwide, Inc.Terremark Worldwide (Nasdaq:TMRK) is a leading global provider of ITinfrastructure services delivered on the industry's most robust and advancedtechnology platform.

Leveraging data centers in the United States, Europe andLatin America with access to massive and diverse network connectivity, Terremarkdelivers government and enterprise customers a comprehensive suite of managedsolutions including managed hosting, colocation, disaster recovery, security andcloud computing services buy neil young . Terremark's Enterprise Cloud computing architecturedelivers the agility, scale and economic benefits of cloud computing tomission-critical enterprise and Web 2.0 applications and its DigitalOps(r)service platform combines end-to-end systems management workflow with acomprehensive customer portal neil southern . More information about Terremark Worldwide can befound at contained in this press release may constitute "forward-lookingstatements" within the meaning of the Private Securities Litigation Reform Actof 1995 neil chords . Terremark's actual results may differ materially from those set forthin the forward-looking statements due to a number of risks, ability tocross-sell across an acquired customer base, ability to increase revenue yieldswithin facilities, ability to refinance existing debt, uncertainties and otherfactors, as discussed in Terremark's filings with the SEC neil lyrics . These factorsinclude, without limitation, Terremark's ability to obtain funding for itsbusiness plans, uncertainty in the demand for Terremark's services or productsand Terremark's ability to manage its growth, the successful integration ofoperations of acquired companies.

Terremark does not assume any obligation toupdate these forward-looking statements.-0-CONTACT:Terremark Worldwide, Inc., MiamiMedia RelationsXavier Investor RelationsHunter free neil young . SOUTH SAN FRANCISCO, Calif., Jan 12 /PRNewswire-FirstCall/ -- SunesisPharmaceuticals, Inc neil discography . (Nasdaq: SNSS) today provided a clinical update onvoreloxin, its novel investigational drug candidate currently being developedin Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer.Theclinical update coincides with the company's attendance at the 27th Annual JPMorgan Healthcare Conference in San Francisco neil tabs . "2008 was an important year for Sunesis, as we have continued to advance thedevelopment of voreloxin in both AML and ovarian cancer.We believe voreloxinhas the potential to be a first-in-class anti-cancer agent for treating thesediseases and potentially other hematologic and solid tumors," said DanielSwisher, Chief Executive Officer and President of Sunesis."We completedenrollment of our Phase 2 platinum-resistant ovarian cancer study and both ofour ongoing AML studies are enrolling well, with 45 AML patients enrolled inthe fourth quarter of 2008 alone.In the first half of 2009, we anticipatereporting additional data from all three of our ongoing voreloxin studies.Weremain on track to initiate a pivotal voreloxin study in AML by the end ofthis year."Sunesis is providing an update on the progress of its voreloxin clinicaltrials as follows:Phase 2 and 1b/2 Studies of Voreloxin in AMLSunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial,known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefitfrom standard induction chemotherapy neil man . Interim results recently presented atthe 50th Annual Meeting of the American Society of Hematology (ASH) show thatvoreloxin induces complete remissions in these poor risk patients.At ASH,outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 ofvoreloxin weekly for three weeks, was reported.Eleven patients achieved acomplete remission (CR) or complete remission without full platelet recovery(CRp), for an overall remission rate of 38 percent.The 30-day all-causemortality rate was 17 percent, which compares favorably to standard inductionchemotherapy.Data on the median duration of response for patients achievinga CR or CRp in Schedule A is not yet available.With Schedule B, 72 mg/m2 of voreloxin weekly for two weeks, Sunesis isexploring if the therapeutic index is improved by eliminating the third dose.

Early data suggest that Schedule B is better tolerated by patients, whilemaintaining anti-leukemic activity.New data on the 21 patients on Schedule Breported on at ASH indicate 6 have achieved a CR or CRp, while 2 are awaitinghematologic count recovery.In addition to improved tolerability, the 30-dayall-cause mortality rate has been reduced to 5 percent (1 of 21) . Additionally, the company is rapidly accruing relapsed or refractory AMLpatients in a Phase 1b/2 clinical trial testing voreloxin in combination withcytarabine given by continuous infusion (Schedule A) or by 2 hr IV infusion(Schedule B).At ASH, Sunesis reported that a maximum tolerated dose (MTD) of80 mg/m2 was established for Schedule A, with 9 CRs or CRps reported in thePhase 1b dose escalation.The Phase 2 portion of this study has now enrolledeight patients with AML in first relapse at the Schedule A MTD and completeremissions have been observed.In addition, Schedule B has completed safetyassessment for the first cohort without dose limiting toxicities, and thesecond cohort is now enrolling at 80 mg/m2 of voreloxin."We are extremely pleased by these interim results for both of our AMLstudies.In the REVEAL-1 study, overall tolerability has improved with theamended dose regimen, while maintaining activity," said Steve Ketchum, SeniorVice President, Research and Development for Sunesis."Our combination studyhas shown complete remissions and a manageable safety profile.Both studiesare continuing to enroll well, and, pending final clinical data, allow us toexplore potential registration strategies in either newly diagnosed or firstrelapse AML populations." Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian CancerEnrollment is complete for the Phase 2 study of voreloxin inplatinum-resistant ovarian cancer.Three schedules of voreloxin have beenstudied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75mg/m2 (N=35) given every four weeks pocahontas young . As reported at the 12th BiennialMeeting International Gynecologic Cancer Society, two complete responses andfive partial responses were observed at 48 mg/m2.Thirty patients (46%)achieved disease control, defined as stable disease for 90 days or more or acomplete or partial response.Median progression free survival is 82 days neil bass . All patients at this dose level are now off-study.Data are maturing for boththe 60 and 75 mg/m2 cohorts .